|Publication number||US5460944 A|
|Application number||US 08/051,253|
|Publication date||24 Oct 1995|
|Filing date||21 Apr 1993|
|Priority date||28 Oct 1991|
|Publication number||051253, 08051253, US 5460944 A, US 5460944A, US-A-5460944, US5460944 A, US5460944A|
|Inventors||Norbert Franken, Nicholas Hoyle, Gunter Pappert|
|Original Assignee||Boehringer Mannheim Gmbh|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (20), Non-Patent Citations (5), Referenced by (6), Classifications (12), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation in part of Ser. No. 967,668, filed Oct. 28, 1992 and now abandoned.
The present invention is concerned with storable conjugates of proteins and horseradish peroxidase (POD conjugates).
In DD 237327 are described proteins, heterocyclic azines and polyalcohols in a medium with a pH value of from 6.0 to 7.5 for the stabilisation of POD (HRP) conjugates. In EP-A 0 303 062, hydroysed chicken albumin and/or calf serum, polyvinylpyrrolidone and/or calcium propionate, ANS (anilinonaphthylsulphonic acid) in tris buffer of pH 7.2 are described for the stabilisation of POD conjugates; U.S. Pat. No. 4,757,016 describes aminopyrine, for example in phosphate, citrate or borate buffer; from U.S. Pat. No. 4,252,896 is known a medium containing ANS and serum protein; U.S. Pat. No. 4,448,882 describes a medium containing 4-aminoantipyrine, ANS and serum protein; and U.S. Pat. No. 4,169,012 describes the use of polyvalent ions of Groups 2 and 3 of the Periodic System. However, POD conjugates in solution can only be stabilised for a limited period of time with these additives. Even after a few days, a distinct decrease of the POD activity or of the stability is observed in immunological tests.
It is an object of the present invention to provide a solutions containing conjugates of POD and immunologically bindable substances with improved stability which can be stored at ambient temperature for a comparatively long period of time and which can be produced in a simple and reproducable way.
Thus, according to the present invention, there is provided a storable solution containing conjugates of POD and immunologically bindable substances, characterised by a pH value of 5.0 to 6.5, adjusted by means of an organic buffer substance with a concentration of 40 to 100 mmol/l, and 0.05 to 1.0 mol/l an aspartate salt.
As POD conjugates, there are preferably used the conjugates of POD as label and of a binder and especially immunological binder substance employed for immunological determination processes. As binder conjugate partners of POD, there are especially preferably used antibodies, fragments thereof, antigens, haptens, biotin and streptavidin.
According to the present invention, as organic buffer substance, it is especially preferred to use Good buffer, citrate buffer and/or 2-(N-morpholino)-ethanesulphonic acid (MES), MES being preferably used.
On the basis of the pH values to be adjusted to one another, of the concentration of the buffer substances and of the presence of the aspartate, outstanding stability results are achieved with the POD conjugate solutions according to the present invention.
In addition, the solutions according to the present invention preferably contain stabilisers, preserving agents and/or inert proteins, namely, especially 0 to 0.4 g/l of stabilisers, 0 to 1 g/l of preserving agents and/or 0 to 20 g/l of inert protein.
Inert proteins (supporting proteins) include, for example, albumins, casein and immunoglobulins. Stabilisers which can be used according to the present invention include, for example, ANS, phenol and dimethylaminoantipyrine. Preserving agents which can be used according to the present invention include, for example, KATHON (5-chloro-2-methyl-4-isothiazoline-3-one and 2-methyl-4-isothiazolin-3-one), OXIPYRION (2-hydroxypyridin-N-oxide) and methyl isothiazolone.
The solutions according to the present invention possess outstanding stabilities. For different POD conjugates, for example MAB-POD or hapten-POD, after storage for 3 weeks at 35° C., the peroxides activity is still 80 to 99% of the initial value.
The aspartate salt is preferably an alkali or alkaline earth metal salt. Ammonium aspartate can also be used. Especially preferred embodiments of the invention utilize either potassium aspartate or magnesium aspartate.
The following Examples are given for the purpose of illustrating the present invention, without limiting it thereto. If nothing otherwise is states, the percentages and parts are by weight.
The test was carried out according to the ELISA test principle as a one-step sandwich test by means of solid phase-bound streptavidin, a biotinylated, monoclonal antibody (MAB-Bi) and a peroxidase-labelled second monoclonal antibody (MAB-POD).
100 μl of sample and 1000 μl of working solution were introduced into a polystyrene test tube coated with streptavidin (production according to EP-A 0 269 092).
MAB-POD (POD activity: 20 U/ml)
40 mmol/l buffer (4-morpholinoethanesulphonic acid, phosphate buffer or citrate buffer) (pH value according to the following Table 1)
0.1 mol/l magnesium aspartate
0.2 g/l 4-dimethylaminoantipyrine
0.1 g/l OXIPYRION (2-hydroxypyridin-N-oxide)
10 g/l bovine immunoglobulin.
1.5 μg/ml MAB-Bi
1/100th POD storage solution
Incubation was carried out for 1 hour at ambient temperature, followed by washing twice with 0.9% aqueous sodium chloride solution, whereafter 1000 μl of substrate solution were added thereto.
100 mmol/l phosphate-citrate buffer (pH 5.0)
1.47 mmol/l sodium perborate
9.1 mmol/1,2,2'-azino-di-(3-ethylbenzthiazoline-6-sulphonic acid) diammonium salt (ABTS®)
After incubation for 30 minutes, the colour formed was determined photometrically at 420 nm.
2.9 ml of substrate solution and 0.1 ml of dilute sample (MAB-POD) were mixed in a cuvette with 1 cm path length and, after mixing, the absorption change was monitored at ambient temperature for 5 minutes at 405 nm.
An average value of the extinction change per minute was determined. The POD activity was determined according to the following equation:
activity=0.8152×A/min (U/ml of sample solution)
Anti-TSH antibody-POD conjugate was stored in POD storage solution (without the addition of MAB-Bi) at different pH values in different buffer substances for 3 weeks at 4° C. and 35° C.
The function of the conjugate was tested according to the process described in Example 1 in the presence of buffer and magnesium aspartate. The POD activity was also tested according to Example 2.
The following Table 1 shows the results obtained:
TABLE 1______________________________________ activity after storage for 3 weeks at 4° C. 3 weeks at 35° C. immune POD immune PODbuffer ion, pH activity activity activity activity______________________________________acetate, pH 6.0 100% 100% 87% 90%phosphate, pH 6.0 100% 100% 78% 100%MES, pH 6.5 100% 100% 87% 100%MES, pH 6.0 100% 100% 87% 100%MES, pH 5.0 100% 100% 82% 100%MES, pH 4.0 100% 100% 43% n.d.phosphate, pH 8.0 100% 100% 62% 100%______________________________________ n.d. = not determined
Table 1 shows that admittedly the POD activity is still present after storage for 3 weeks at 35° C. but small losses in the activity are only seen when the pH value of the buffer is from 5 to 6.5.
As described in Example 3, anti-TSH antibody-POD conjugate (activity 20 U/ml in 40 mmol/ml 4-MES buffer at pH 6.0) was stored in the presence of different magnesium aspartate concentrations.
The stability of the solutions was tested after 3 weeks storage in a test according to Example 1. The following Table 2 shows the results obtained:
TABLE 2______________________________________magnesium aspartate activity after storage forconcentration 3 weeks at 4° C. 3 weeks at 35° C.______________________________________0.00 mol/l 100% 64%0.05 mol/l 100% 84%0.10 mol/l 100% 77%0.25 mol/l 100% 81%______________________________________
Table 2 shows that magnesium aspartate has a positive influence on the performance of the anti-TSH antibody conjugates.
The POD-hapten and antibody conjugates mentioned in Table 3, with an average enzymatic activity of 0.4 to 20 U/ml, were stored for 3 weeks at 4° C. and 35° C. in a solution of 40 mmol/l 4-MES(pH 5.0 to 6.0), 0.1 g/l oxipyrion and 10 g/l bovine immunoglobulin. Subsequently, an appropriate function test for the antigen was carried out analogously to Example 1. The following Table 3 shows the results obtained:
TABLE 3______________________________________POD conjugate with activity after storage for0.1 mol/l aspartate 3 weeks 4° C. 3 weeks 35° C.______________________________________anti-TSH MAB-POD 100% 85%anti-TSH-PAB-POD 100% 89%anti-LH MAB-POD 100% 86%anti-FSH MAB-POD 100% 84%anti-HCG MAB-POD 100% 79%anti-CEA MAB-POD 100% 77%______________________________________
The parameters of example 4 were followed, with one exception. Rather than the magnesium salt, a solution of potassium aspartate (0.24 mole/l) was used. Again, using all parameters of Example 4, immune activity was checked after three weeks storage at 4° C. The activity was 100%. After three weeks at 35° C., the immune activity was found to be 87%.
The foregoing demonstrates the usefulness of aspartate salts in stabilizing the immune activity of conjugates of peroxidase and immunologically bindable substances. Thus, in its broadest embodiments the invention relates to stabilized compositions which comprise at least one conjugate of peroxidase and an immunologically bindable component, an organic buffer at a concentration of from about 40 to about 100 mmol/l, and an aspartate salt at a concentration of from about 0.05 to about 1.0 mol/l. The composition is in the form of a solution and has a pH of from about 5.0 to about 6.5. Preferred aspartate salts are alkali metal, alkaline earth metal, and ammonium salts. Especially preferred are compositions comprising one of magnesium aspartate or potassium aspartate. Preferred organic buffers are GOOD buffer, citrate buffer, or MES (i.e., 2-(N-morpholino)-ethane sulphonic acid). The compositions may contain additional ingredients, including stabilizers, preserving agents, and insert proteins. Stabilizers, when used are preferably used at concentrations up to about 0.4 g/l. When preserving agents are used, concentrations up to about 0.1 g/l are preferred. Insert proteins, when present, are used at concentrations up to about 20 g/l.
Examples of suitable stabilizers are anilinonapthyl sulphonic acid, phenol, or dimethyl amino antipyrene. Preferred preservatives are KATHAN, OXYPYRION, or methylisothiazoline, and the inert protein is preferably albumin, casein, or immunoglobulin. The immune component, i.e., the immunologically bindable substance, includes any and all of the materials recognized as such by the art, including antibodies, antibody fragments, such as Fab fragments, antigens, haptens, biotin, avidin, and streptavidin. Other aspects of the invention will be clear to the skilled artisan and need not be set forth here.
It will be understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4169012 *||9 Sep 1977||25 Sep 1979||Akzona Incorporated||Stabilized peroxidase reagent for enzyme immunoassay|
|US4208479 *||14 Jul 1977||17 Jun 1980||Syva Company||Label modified immunoassays|
|US4299916 *||26 Dec 1979||10 Nov 1981||Syva Company||Preferential signal production on a surface in immunoassays|
|US4394512 *||23 Jan 1981||19 Jul 1983||Boehringer Mannheim Gmbh||1-(Substituted phenyl) aminoantipyrin compounds|
|US4448882 *||12 Jul 1982||15 May 1984||Hoffmann-La Roche Inc.||Stabilized peroxidase compositions|
|US4476223 *||23 Dec 1982||9 Oct 1984||Boehringer Mannheim Gmbh||Process for the stabilization of aqueous solutions of cholesterol esterase from pseudomonas|
|US4543326 *||12 Nov 1982||24 Sep 1985||Wako Pure Chemical Industries, Ltd.||Stabilization of oxidase|
|US4757016 *||4 Mar 1986||12 Jul 1988||Boehringer Mannheim Gmbh||Process for stabilizing the activity of peroxidase in solution|
|US4764468 *||4 Mar 1986||16 Aug 1988||Boehringer Mannheim Gmbh||Process for stabilizing the activity of peroxidase in solution|
|US4826776 *||24 Nov 1987||2 May 1989||Pharmacia Ab||Method for determining hyaluronic acid, and a reagent kit for said method|
|US4833073 *||27 Jan 1987||23 May 1989||Hoffmann-La Roche Inc.||Immunoassay for tetrahydrocannabinol metabolites|
|US4914040 *||3 Mar 1988||3 Apr 1990||Boehringer Mannheim Gmbh||Reagent and method for determination of a polyvalent substance using an immunoaggregate|
|US5075221 *||7 Oct 1988||24 Dec 1991||Eastman Kodak Company||Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations|
|US5122453 *||3 May 1988||16 Jun 1992||Technicon Instruments Corporation||Method for discriminating surface stained lymphocytes|
|US5166054 *||2 Jan 1991||24 Nov 1992||Becton, Dickinson And Company||Method for immunoassay using lactoperoxidase, starch and iodine|
|EP0080304A1 *||11 Nov 1982||1 Jun 1983||Wako Pure Chemical Industries, Ltd.||Stabilization of oxidase|
|EP0361088A1 *||25 Aug 1989||4 Apr 1990||TRIGON CHEMIE GmbH||Aspartic-acid derivatives and process for their preparation|
|EP0426552A1 *||29 Oct 1990||8 May 1991||Cis Bio International||Composition of stabilized peroxidase, for use as immuno-enzymatic assays|
|EP0456309A1 *||2 May 1991||13 Nov 1991||Johnson & Johnson Clinical Diagnostics, Inc.||Use of heme-containing proteins as stabilizers for enzyme-labeled immunoreactants|
|EP0487301A1 *||19 Nov 1991||27 May 1992||BEHRINGWERKE Aktiengesellschaft||Method of stabilizing enzyme conjugates|
|1||*||Good, N. E. et al. Hydrogen Ion Buffers for Biological Research. Biochemistry 5:467 477, 1966.|
|2||Good, N. E. et al. Hydrogen Ion Buffers for Biological Research. Biochemistry 5:467-477, 1966.|
|3||*||Harlowe, E. et al. Antibodies: A Laboratory Manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1988. p. 396.|
|4||*||Sigma Chemical Co. 1988 Catalog. p. 306.|
|5||*||Windholz, M., ed. The Merck Index, 10th edition. Rathway, N.J.: Merck and Co., 1983, p. 71, entry 480.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7169754||11 May 2001||30 Jan 2007||Hoffmann-La Roche Inc.||Erythropoietin composition|
|US7202208||17 Feb 2004||10 Apr 2007||Hoffman-La Roche Inc.||Erythropoietin composition|
|US20020037841 *||11 May 2001||28 Mar 2002||Apollon Papadimitriou||Erythropoietin composition|
|US20040147431 *||17 Feb 2004||29 Jul 2004||Apollon Papadimitriou||Erythropoietin composition|
|US20060023808 *||17 May 2005||2 Feb 2006||Hajivandi Mahbod R||Compositions, kits, and methods for calibration in mass spectrometry|
|US20120205592 *||13 Jan 2012||16 Aug 2012||Life Technologies Corporation||Compositions, kits, and methods for calibration in mass spectrometry|
|U.S. Classification||435/7.9, 435/28, 435/188, 436/826, 435/27, 435/962, 424/94.3|
|Cooperative Classification||G01N33/535, Y10S435/962, Y10S436/826|
|29 Jul 1997||CC||Certificate of correction|
|15 Apr 1999||FPAY||Fee payment|
Year of fee payment: 4
|24 Oct 2003||LAPS||Lapse for failure to pay maintenance fees|
|23 Dec 2003||FP||Expired due to failure to pay maintenance fee|
Effective date: 20031024